FDG-PET Imaging in Complicated Diabetic Foot

StatusActive, Not Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Feb 2026 to Feb 2027v15
  2. Primary and study completion dates: Feb 2025 to Feb 2026v14
  3. Primary and study completion dates: Feb 2024 to Feb 2025v13
  4. Primary and study completion dates: Feb 2023 to Feb 2024v12
  5. Primary and study completion dates: Feb 2022 to Feb 2023v11
Show 9 earlier versionsHide 9 earlier versions
  1. Primary and study completion dates: Jan 2021 to Feb 2022v10
  2. Primary and study completion dates: Jan 2020 to Jan 2021v9
  3. 2 versions Re-verified since May 3, 2018, no change to tracked fieldsv7-v8
  4. Primary completion date: Jan 2017 to Jan 2020
    • Study completion date: Jan 2020
    v6
  5. Primary completion date: Jan 2016 to Jan 2017v5
  6. Primary completion date: Jan 2014 to Jan 2016v4
  7. Phase: Phase 2/3 to Not specifiedv3 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Jan 2014
    • Study description revised
    • Site details revised
  8. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The main objective of the proposed research study is to determine the potential utilization of \[18-F\] Fluorodeoxyglucose (FDG) positron emission tomography (PET) in patients with complicated diabetic foot, especially in the diagnosis or exclusion of osteomyelitis in this setting. We intend to validate and establish the necessary criteria for making such a diagnosis and determine the accuracy of the technique through comparison with other existing modalities, including MRI, and patient outcome. We expect that at the completion of the proposed research, the role of these powerful imaging modalities will be clearly defined in the management of patients with this challenging and serious complication.
Trial Details
NCT Number NCT00194298
Lead Sponsor University of Pennsylvania
Collaborators: National Institutes of Health (NIH)
Conditions
(from sponsor)		 Diabetic Foot Disease
Related terms Hypoxia, Osteomyelitis
Enrollment 240 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov